A5076940642- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Nonmelanoma Skin Cancer Studies
- Cutaneous lymphoproliferative disorders research
- Immunotherapy and Immune Responses
- Brain Metastases and Treatment
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Polyomavirus and related diseases
- Chronic Lymphocytic Leukemia Research
- Chemotherapy-related skin toxicity
- Nail Diseases and Treatments
- Cancer and Skin Lesions
- melanin and skin pigmentation
- Protein Degradation and Inhibitors
- Autoimmune Bullous Skin Diseases
- Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Acne and Rosacea Treatments and Effects
- Drug-Induced Adverse Reactions
- Autoimmune and Inflammatory Disorders
- Psoriasis: Treatment and Pathogenesis
Inserm
2021-2025
Université de Bordeaux
2018-2025
Bordeaux Population Health
2023-2025
Centre Hospitalier Universitaire de Bordeaux
2016-2025
Hôpital Saint-André
2014-2024
Sanofi (France)
2021-2024
Université de Lille
2024
Centre Hospitalier Universitaire de Lille
2024
Hôpital Pellegrin
2023
University Dermatology
2021
Lentigo maligna (LM) is a melanoma subtype that occurs on sun-damaged skin in the elderly. Dermal invasive developing from LM called (LMM) and has same prognosis as other subtypes. The standard treatment for surgery, which offers lowest risk of recurrence. Alternatives exist, however, including radiotherapy (RT). Describe real-life cohort patients with LM/LMM treated RT assess prognostic factors This retrospective monocentric study conducted Bordeaux University Hospital. All or LMM between...
PURPOSE Emerging evidence suggests a correlation between the tumor mutational burden (TMB) and response to programmed cell death-1 protein (PD-1) monotherapy across multiple cancer types. In skin cancers, as high TMB is mostly because of ultraviolet (UV) exposure, we hypothesized primary melanoma cutaneous location according sun exposure anti–PD-1 monotherapy. METHODS The aim this study was analyze, in advanced melanoma, relationship TMB, locations PD-1 inhibitors. We conducted prospective...
The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature.In this retrospective multicenter national real-life study, we enrolled patients who had rechallenged with an after achieving a first course ICI, which was subsequently interrupted. primary objective to evaluate tumor response, while secondary objectives included...
Cardiac metastasis from melanoma is a rare but clinically significant condition often underdiagnosed because of its asymptomatic nature. This retrospective case series examines six patients with metastatic treated at the University Hospital Bordeaux who were incidentally found to have cardiac metastases during follow-up. The immune checkpoint inhibitors (ICIs) either alone or combined surgical excision lesions. Outcomes mixed, three (50%) achieving complete response, one (16.7%) partial and...
Retronychia is a form of post-traumatic ingrowing nail disease that involves proximal plate embedding into the fold, with multiple generations beneath nail. This probably underdiagnosed because incomplete clinical forms. The aim this study was to report and aetiological variants retronychia evaluate their therapeutic outcome. A retrospective review performed on 18 patients who were seen in our institution between 2007 2013. diagnostic criteria for paronychia interruption growth. female...
Anti-PD-1 has dramatically improved the survival of patients with advanced melanoma. However, there is a lack data on maintenance response after treatment discontinuation. We aimed to evaluate progression-free (PFS) metastatic melanoma anti-PD-1 interruption for objective (OR) or limiting toxicity during clinical trials.All who stopped single-agent antibodies were included between April 2014 and January 2019 in our institution (data cut-off, September 10th, 2019). Clinical biological factors...
Diffusion chamber granulopoiesis was studied in irradiated mice injected with anti-CSF serum. Total cellularity, proliferative and nonproliferative granulocytes were markedly suppressed by 4 days injection of antiserum. Moreover, granulocytic stem cells decreased. This suggests that CSF is necessary for maintaining the integrity cell inducing differentiating granulopoiesis.
Clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 (PD-1) remain unknown.To better characterize the occurrence of anti-PD-1.The present single-center ambispective cohort study included melanoma treated anti-PD-1. Progression-free survival, overall and objective tumor response were compared between those without using Kaplan-Meier curves log-rank test. Demographic clinical evaluated multivariate logistic regression.Of 457 study, developed 85 patients....
Abstract Purpose Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in white-skinned populations. There little information on epidemiology of cSCC, and even less advanced cases (acSCC). Therefore, we analyzed acSCC patients to describe their characteristics, management, outcomes over time. Methods A single-center retrospective study was conducted a period 5 years, including all who started systemic therapy for acSCC. The patient cSCC response therapy, survival were...
Aims The aim of this multicentre study was to harmonize programmed death‐ligand 1 (PD‐L1) immunohistochemistry (IHC) and melanoma scoring. To provide a reference for PD‐L1 expression independently the IHC protocol, mRNA compared with IHC. Methods results Standardized assays (22C3, 28–8, SP142, SP263) laboratory‐developed tests (QR1, 22C3) were evaluated on three platforms training set (seven cases). determined by RNAscope (CD274/PD‐L1 probe) analysed image analysis. findings scored seven...
Prescribing anti-programmed death-1 (PD-1) immunotherapy for advanced melanoma is currently not restricted by any biomarker assessment. Determination of programmed death-ligand-1 (PD-L1)-expression status technically challenging and mandatory, because negative tumours also achieve therapeutic responses. However, reproducible biomarkers predictive a response to anti-PD-1 therapy could contribute improving decision-making. This retrospective study on 70 metastatic patients was undertaken...
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced melanoma. Combination ICI with ipilimumab cytotoxic T-lymphocyte antigen-4 and nivolumab [anti-programmed cell death-1 (PD-1)] improves tumoral response compared to anti-PD1 monotherapy in melanoma patients, but is associated more severe multiple immune-related adverse events. We report first case aseptic cystitis induced by combination a 61-year-old patient. She described after two infusions, diarrhea,...
Abstract Background Currently, treatment options for patients with advanced melanoma who experience failed immunotherapy or targeted therapy are lacking. Recent studies suggest the antitumor activity of combined pembrolizumab and lenvatinib in progressing on immunotherapy. Herein, we report clinical outcomes a programmed cell death protein-1 inhibitor (PD-1) this population. Materials Methods This French multicenter real-world study was conducted between September 2020 July 2023. The primary...
The metabolism of the brain, as estimated by glucose taken from blood in passing through it, is agreement with that determined analogous studies oxygen and carbon dioxide changes. Brain so at least 20 times intense resting muscle. This average does not differentiate higher respiration gray matter white, large amount non-neural elements, similar factors tending to dilute a much value for nerve cells proper. Insulin uniquely influence brain sugar utilization.
Objective Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety ICI rechallenge this setting. We aimed to assess the rate clinical features associated ICI-IA flare/recurrence on rechallenge. Methods conducted a multicentre observational study who started second more than 3 months after discontinuation four...
While several studies reported the influence of co-medications on immune checkpoint therapy and chemotherapy, it remains poorly studied with targeted therapy. Targeted therapies inhibiting BRAF MEK had significantly improved management advanced melanoma BRAFV600 mutation over last decade, we aimed to investigate possible co-mediations efficacy toxicity these (TT).